The Role of Orexins In Sleep-Wake Regulation
The orexin signaling system is a central promoter of wakefulness
NORMAL SLEEP-WAKE REGULATION
Daytime
In the daytime,
orexins help us
stay awake
Night
At night,
orexin activity is very low
letting us sleep
INSOMNIA
Insomnia
In insomnia,
excess orexins prevent
us from sleeping
DAYVIGO
DAYVIGO
DAYVIGO blocks
orexin activity
Normal sleep-wake regulation occurs when the wake-promoting pathway predominates during the day, and the sleep-promoting pathway predominates at night.
In insomnia, patients have difficulty falling asleep or staying asleep as a result of an imbalance and conflict between these two pathways.
Blocking the binding of wake-promoting orexins is thought to suppress the wake drive.
- Orexin-producing neurons
- Wake-controlling neurons expressing orexin receptors
What is DAYVIGO™
- A dual orexin receptor antagonist (DORA). The Orexin neuropeptide
signaling system is a central promoter of wakefulness. - Blocking the binding of wake-promoting neuropeptides orexin A and
orexin B to receptors OX1R and OX2R is thought to suppress wake drive
DAYVIGO is an antagonist of both orexin receptors. It does not
work by increasing GABA activity2
- Orexin-producing neurons
- Wake-controlling neurons expressing orexin receptors
DAYVIGO™ blocks orexin activity at night
DAYVIGO prevents orexins from keeping the "wake drive" on.
•DAYVIGO blocks the orexin signaling system, thought to suppress the wake drive.
Sleep disturbance may be the presenting manifestation of a physical and/or psychiatric disorder.
Consequently, a decision to initiate symptomatic treatment of insomnia should only be made after the
patient has been carefully evaluated.
DAYVIGO™ is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or
sleep maintenance.
Click here for additional safety information and for a link to the product monograph, discussing
contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical
use.